Drugs.com - New Drug Approvals

Indivior Announces FDA Approval of Label Changes for Sublocade (buprenorphine extended-release) Injection

Richmond, VA, February 24, 2025 – Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for Sublocade® including a rapid...

Mar 3, 2025 - 00:08
 0
Indivior Announces FDA Approval of Label Changes for Sublocade (buprenorphine extended-release) Injection
Richmond, VA, February 24, 2025 – Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for Sublocade® including a rapid...
Read More

Tags:

Previous Article

Hydrogen Is An Indirect Greenhouse Gas So Now Hydrogen Proponents Are Denying It

Next Article

Milan: Footloose but not fancy-free this season

Related Posts

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to ...

Feb 17, 2025  0

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar ...

Feb 9, 2025  0

FDA Approves Alhemo (concizumab-mtci) to Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors

FDA Approves Alhemo (concizumab-mtci) to Prevent or Red...

Feb 9, 2025  0